Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: Insights from the GISSI-HF and Val-HeFT trials

European Journal of Heart Failure

Volumn 17, Issue 4, 2015, Pages 424-433

  Rossignol, Patrick ^a,b,c   Masson, Serge ^d   Barlera, Simona ^d   Girerd, Nicolas ^a,b,c   Castelnovo, Angelo ^d   Zannad, Faiez ^a,b,c   Clemenza, Francesco ^e   Tognoni, Gianni ^d   Anand, Inder S ^f   Cohn, Jay N ^g   Anker, Stefan D ^h,i   Tavazzi, Luigi ^j   Latini, Roberto ^d  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c INSERM UMR S 1116 University of Lorraine   (France)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^f VA MEDICAL CENTER   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^j ES Health Science Foundation   (Italy)

more..

Author keywords

Cachexia; Heart failure; Plasma volume; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA VOLUME; PRIORITY JOURNAL; PROGNOSIS; SELF CONCEPT; WEIGHT REDUCTION; BLOOD; CACHEXIA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; C-REACTIVE PROTEIN; CACHEXIA; CLINICAL TRIALS AS TOPIC; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PLASMA VOLUME; PROGNOSIS; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 84926202169     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.240     Document Type: Article

References (30)

1. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH,. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38: 789-795.
2. Lavie CJ, Milani RV, Ventura HO,. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-1932.
3. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ,. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050-1053.
4. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S,. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet 2003; 361: 1077-1083.
5. Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Anker SD, Swedberg KB,. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (charm) programme. Eur Heart J 2008; 29: 2641-2650.
6. von Haehling S, Lainscak M, Springer J, Anker SD,. Cardiac cachexia: A systematic overview. Pharmacol Ther 2009; 121: 227-252.
7. Pureza V, Florea VG,. Mechanisms for cachexia in heart failure. Curr Heart Fail Rep 2013; 10: 307-314.
8. Anker MS, von Haehling S, Springer J, Banach M, Anker SD,. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Int J Cardiol 2013; 162: 73-76.
9. Strauss MB, Davis RK, Rosenbaum JD, Rossmeisl EC,. Water diuresis produced during recumbency by the intravenous infusion of isotonic saline solution. J Clin Invest 1951; 30: 862-868.
10. Kalra PR, Anagnostopoulos C, Bolger AP, Coats AJ, Anker SD,. The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 2002; 39: 1901-1908.
11. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F,. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an ephesus (eplerenone post-acute myocardial infarction heart failure efficacy and survival study) substudy. J Am Coll Cardiol 2011; 58: 1958-1966.
12. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G,. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230.
13. Cohn JN, Tognoni G,. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
14. Barlera S, Tavazzi L, Franzosi MG, Marchioli R, Raimondi E, Masson S, Urso R, Lucci D, Nicolosi GL, Maggioni AP, Tognoni G,. Predictors of mortality in 6975 patients with chronic heart failure in the gruppo italiano per lo studio della streptochinasi nell'infarto miocardico-heart failure trial: proposal for a nomogram. Circ Heart Fail 2013; 6: 31-39.
15. Harrell FE,. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. Berlin: Springer; 2001.
16. Pencina MJ, D'Agostino RB Sr, Steyerberg EW,. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
17. Shah R, Gayat E, Januzzi JL, Jr,., Sato N, Cohen-Solal A, diSomma S, Fairman E, Harjola VP, Ishihara S, Lassus J, Maggioni A, Metra M, Mueller C, Mueller T, Parenica J, Pascual-Figal D, Peacock WF, Spinar J, van Kimmenade R, Mebazaa A,. Body mass index and mortality in acutely decompensated heart failure across the world: A global obesity paradox. J Am Coll Cardiol 2014; 63: 778-785.
18. Clark AL, Fonarow GC, Horwich TB,. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis 2014; 56: 409-414.
19. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO,. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013; 1: 93-102.
20. Lavie CJ, Ventura HO,. Analyzing the weight of evidence on the obesity paradox and heart failure-is there a limit to the madness? Congest Heart Fail 2013; 19: 158-159.
21. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN,. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol. 2014; 63: 1345-1354.
22. Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK, Lopez-Jimenez F,. The prognostic importance of weight loss in coronary artery disease: A systematic review and meta-analysis. Mayo Clin Proc 2014; 89: 1368-1377.
23. Alpert MA, Omran J, Mehra A, Ardhanari S,. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog Cardiovasc Dis 2014; 56: 391-400.
24. Song EK, Lee Y, Moser DK, Dekker RL, Kang SM, Lennie TA,. The link of unintentional weight loss to cardiac event-free survival in patients with heart failure. J Cardiovasc Nurs 2014; 29: 439-447.
25. Szabo T, Postrach E, Mahler A, Kung T, Turhan G, von Haehling S, Anker SD, Boschmann M, Doehner W,. Increased catabolic activity in adipose tissue of patients with chronic heart failure. Eur J Heart Fail 2013; 15: 1131-1137.
26. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ,. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-534.
27. Xin W, Wei W, Li X,. Effects of fish oil supplementation on inflammatory markers in chronic heart failure: A meta-analysis of randomized controlled trials. BMC Cardiovasc Disord; 12: 77.
28. Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, Flyvbjerg A, Faber J,. Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: A prospective study. Metabolism 2014; 63: 141-149.
29. Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, Schwarz P, Faber J,. Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine 2013; 43: 626-634.
30. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P,. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001; 38: 963-968.